Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

Keywords

NivolumabHepatocellular carcinomaMedicineOpen labelOncologyInternal medicinePhase (matter)Clinical trialImmunotherapyCancerChemistry

Affiliated Institutions

Related Publications

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn , Masafumi Ikeda , Andrew X. Zhu +17 more

PURPOSE The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death r...

2020 Journal of Clinical Oncology 1120 citations

Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC.

Julie R. Brahmer , Naiyer A. Rizvi , Jose Lutzky +7 more

8021^ Background: Lung cancer is the leading cause of cancer death in both men and women. PD-L1 is upregulated in NSCLC and may be associated with a poor prognosis. MEDI4736 is ...

2014 Journal of Clinical Oncology 78 citations

Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up.

Charles G. Drake , David F. McDermott , Mario Sznol +10 more

4514 Background: Programmed death-1 (PD-1) is an immune checkpoint receptor that negatively regulates T-cell activation. PD-L1, a PD-1 ligand, has been associated with poor prog...

2013 Journal of Clinical Oncology 55 citations

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa , George Lau , Masatoshi Kudo +28 more

BACKGROUND: A single, high priming dose of tremelimumab (anti-cytotoxic T lymphocyte–associated antigen 4) plus durvalumab (anti–programmed cell death ligand-1), an infusion reg...

2022 NEJM Evidence 1193 citations

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer , Nizar M. Tannir , Ray McDermott +29 more

Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previo...

2018 New England Journal of Medicine 4403 citations

Publication Info

Year: 2017
Type: article
Volume: 389
Issue: 10088
Pages: 2492-2502
Citations: 4168
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

4168

OpenAlex

Cite This

APA Style

                            
                                
                                    Anthony B. El-Khoueiry, 
                                
                                    Bruno Sangro, 
                                
                                    Thomas Yau
                                
                                et al.
                            
                            (2017). 
                            Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. 
                            The Lancet
                            , 389
                            (10088)
                            , 2492-2502.
                            https://doi.org/10.1016/s0140-6736(17)31046-2
                        

Identifiers

DOI: 10.1016/s0140-6736(17)31046-2